ARTA
RVNC

A.R.T. Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

A.R.T. Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,000
Closed -$274K – 1771
2018
Q2 		$274K Sell
10,000
-55,600
-85% -$1.67M 0.01% 1140
2018
Q1 		$2.02M Buy
65,600
+3,500
+6% +$113K 0.08% 380
2017
Q4 		$2.22M Buy
62,100
+39,200
+171% +$1.13M 0.1% 337
2017
Q3 		$630K Buy
22,900
+11,200
+96% +$272K 0.03% 735
2017
Q2 		$308K Buy
+11,700
New +$261K 0.02% 995
2015
Q3 		– Sell
-16,460
Closed -$526K – 1644
2015
Q2 		$526K Buy
+16,460
New +$423K 0.02% 976

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

A.R.T. Advisors's RVNC Position: Q3 2018 in Review

A.R.T. Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2018, closing a stake of 10,000 shares — an estimated $274K sold.

A.R.T. Advisors first reported a position in RVNC in Q2 2015 and held it in 6 quarters. The position peaked at $2.22M in Q4 2017. 110 funds tracked by Wall St. Rank hold RVNC as of Q3 2018.

  • A.R.T. Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 10,000 Revance Therapeutics, Inc. shares in Q3 2018, an estimated $274K.
  • A.R.T. Advisors first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 6 quarters.
  • A.R.T. Advisors's Revance Therapeutics, Inc. position peaked at $2.22M in Q4 2017.
  • 110 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2018.

Based on A.R.T. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.